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Background: Molecular characteristics of cancer vary between individuals. In future, most trials will require assessment of biomarkers to allocate
patients into enriched populations in which targeted therapies are more likely to be effective. The MRC FOCUS3 trial is a feasibility study to assess
key elements in the planning of such studies.
Patients and Methods: Patients with advanced colorectal cancer were registered from 24 centres between February 2010 and April 2011. With
their consent, patients’ tumour samples were analysed for KRAS/BRAF oncogene mutation status and topoisomerase 1 (topo-1)
immunohistochemistry. Patients were then classified into one of four molecular strata; within each strata patients were randomised to one of
two hypothesis-driven experimental therapies or a common control arm (FOLFIRI chemotherapy). A 4-stage suite of patient information sheets
(PISs) was developed to avoid patient overload.
Results: A total of 332 patients were registered, 244 randomised. Among randomised patients, biomarker results were provided within 10 working
days (w.d.) in 71%, 15w.d. in 91% and 20w.d. in 99%. DNA mutation analysis was 100% concordant between two laboratories. Over 90% of
participants reported excellent understanding of all aspects of the trial. In this randomised phase II setting, omission of irinotecan in the low topo-1
group was associated with increased response rate and addition of cetuximab in the KRAS, BRAF wild-type cohort was associated with longer
progression-free survival.
Conclusions: Patient samples can be collected and analysed within workable time frames and with reproducible mutation results. Complex multi-
arm designs are acceptable to patients with good PIS. Randomisation within each cohort provides outcome data that can inform clinical practice.
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Cancer is the product of a somatic evolutionary process, in which
successive advantageous genetic and epigenetic alterations drive
the progression of the disease (Greaves and Maley, 2012). Although
current knowledge indicates many similar changes in different
cancers, the number of possible combinations of changes even
within a given anatomical/histological type such as colorectal
cancer (CRC) is very large (The Cancer Genome Network Atlas,
2012). This raises a major challenge in the search for effective
therapies that target the properties of any given cancer, especially
for advanced disease where clonal evolution and the selective
pressure of prior therapies drive increasing diversity and resistance
to subsequent therapy (Sequist et al, 2011; Gerlinger et al, 2012).
This emerging understanding of the heterogeneity of cancer is a
major challenge to clinical trialists and demands new methodol-
ogies for testing novel therapies.
Fundamental to this challenge is the identification of biomar-
kers that help enrich the evaluated population for benefit from a
specific therapy. In CRC, the use of epidermal growth factor
receptor (EGFR)-targeted therapy has led to the discovery of
the importance of KRAS and recently NRAS mutations (Douillard
et al, 2013) in prediction of lack of response to that therapy and
association of BRAF mutation with a particularly poor prognosis in
advanced CRC (ACRC; Lievre et al, 2006; Karapetis et al, 2008;
Maughan et al, 2011). Further biomarker candidates under
evaluation as potentially predicting lack of benefit from anti-EGFR
therapy are PI3K mutations and loss of PTEN expression (De
Roock et al, 2010; Seymour et al, 2013).
This paper reports the results of the MRC FOCUS3 trial
(ISRCTN83171665), a randomised feasibility trial for the selection
of therapy for patients with ACRC based on their KRAS and BRAF
mutation status as well as their topoisomerase 1 (topo-1)
expression status.
MATERIALS AND METHODS
Trial design. Patients were registered on the day they provided
written consent for the release of a tumour sample. Upon
determination of their biomarker status, patients were allocated
to one of four molecular subgroups for randomisation: (1) low
topo-1 expression levels and both KRAS and BRAF wild type,
(2) low topo-1 and either KRAS- or BRAF-activating mutations,
(3) high topo-1 and both KRAS and BRAF wild type and (4) high
topo-1 and either KRAS or BRAF mutations. These randomisation
subgroups correspond to the prior hypotheses that: (1) in patients
with low topo-1 tumours, FU alone is similarly effective and
therefore preferable to irinotecan/FU combination (Braun et al,
2008); (2) in patients with KRAS/BRAF wild-type tumours,
anti-EGFR therapy improves outcomes (Van Cutsem et al, 2009);
(3) in patients with high topo-1 tumours, addition of oxaliplatin to
irinotecan/FU improves outcomes (Braun et al, 2008) and (4) in
patients with KRAS/BRAF-mutated tumours, anti-VEGF therapy
might improve outcomes. There was no specific rationale for a
biologically targeted therapy in patients with KRAS mutations;
however, there were data suggesting benefit of bevacizumab (Ince
et al, 2005).
Patients were randomised centrally by the MRC CTU via
telephone using minimisation and allocated in a 1 : 1 : 1 ratio to the
control arm (A) common to each of the four subgroups or one of
two experimental regimens (Figures 1 and 2). If either molecular
test failed, patients could still be randomised in a 1 : 1 ratio based
on the results available (Figure 1). Treatment allocation was not
masked. Randomisation was stratified by standard clinical prog-
nostic factors.
Patients. Eligibility criteria were age X18 years, colorectal
adenocarcinoma, inoperable metastatic or locoregional RECIST
measurable disease, no previous chemotherapy for metastases,
WHO performance status 0–2 and good organ function (Maughan
and Meade, 2010). Written informed consent for both molecular
testing and randomisation was required.
Outcome measures and sample size. The primary outcome
measures for FOCUS3 were process outcomes, namely, in this
national multi-site setting, how frequently the target could be met
ofp10w.d. between the date of registration and: (1) the provision
of results to the investigator and (2) randomisation.
The target sample size was 240 patients; if4226 tumour blocks
were processed within 10w.d., we could reliably state that X90%
samples could be analysed within that time frame. If o206 blocks
were processed within 10w.d., we could reliably exclude a
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Figure 1. Trial design.
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turnaround rate of 90% (i.e., the upper 95% confidence limit would
exclude 90%).
Secondary outcome measures included toxicity, response rates
(RRs) and progression-free survival (PFS) of the different regimens
within each molecular subgroup; reproducibility of biomarker
results and attitudes of patients to the study design, the consent
process and refusal rates for trial entry.
Informed consent and patients attitudes to the trial design. A
staged set of patient information sheets (PISs) was developed with
input from patients, carers and nursing staff: PIS 1 explained the
need for further analyses of tumour tissue using a very simple
diagram and no technical details (see Figure 2), PIS2, given to
patients before results of their molecular tests were known, covered
the general issues of a three arm RCT and treatment side-effects.
PIS3, in four specific versions a–d, describing the three arm
randomisation for each of the four molecular sub-types (1–4) was
given to patients before randomisation. PIS4, versions a–e,
contained full details of the five treatment regimens (A–E).
Patient understanding of the information was captured on a
questionnaire delivered immediately following their reading of the
stage 2 PIS.
Attitudes of participants to trial entry, understanding and
experience, particularly to the proposed 2 weeks time for tumour
testing before treatment allocation, were evaluated by one-to-one
semi-structured interviews using interpretative phenomenological
analysis in a subgroup of randomised patients (Smith and Osborn,
2003).
Sample collection and analysis process. The clinical research
nurse (CRN) at the recruiting hospital requested the patients’
diagnostic FFPE block. Histopathology agreements were in place
between MRC and all diagnostic hospitals outlining the trial
rationale and stressing the importance of sending blocks promptly
to the central laboratories. The MRC CTU team actively tracked
samples throughout the biomarker analysis process. Upon
reconfirmation of eligibility, and with their consent, patients were
randomised.
Biomarker analysis. Analysis of DNA extracted from macro-
dissected FFPE sections of KRAS codons 12, 13 and 61 and BRAF
codon 600 was each performed by Pyrosequencing (details in
Supplementary Appendix).
Topo-1 protein expression was identified using a topo-1 antibody
(NCL-TOPO1; Leica, Wetzlar, Germany; details in Supplementary
Appendix). Each case was scored on the basis of the percentage of
positive tumour cells (o10% scored low, 410% high).
Quality assurance of biomarker analysis. Fifty samples were
blinded and exchanged between the two laboratories before the
trial and analysed for KRAS and BRAF mutation status.
Throughout the trial both laboratories took part in external quality
assessment (UK NEQAS) for KRAS. Topo-1 IHC was compared
between laboratories.
Interventions and assessments. The five treatment regimens were
all based on the 2-weekly FOLFIRI regimen – folinic acid and
irinotecan followed by bolus and infusional 5-fluouracil (5-FU;
Douillard et al, 2000): (A) Control: FOLFIRI, (B) omits irinotecan:
LV5FU2, (C) adds oxaliplatin: FOLFOXIRI (FOLFIRI and
oxaliplatin), (D) FOLFIRI plus cetuximab and (E) FOLFIRI plus
bevacizumab. Doses in (C) were dependent on patient age and
WHO performance status. The chemotherapy regimens FOLFIRI
and LV5FU2 are internationally recognised acronyms. The actual
regimens used in FOCUS3 were established in the UK (Cheeseman
et al, 2002; Leonard et al, 2002). They have been used in large
numbers of patients, have been shown to be both efficacious and
safe (Seymour et al, 2007) and will be referred to as FOLFIRI and
LV5FU2 in this paper. The FOLFIRI regimen consisted of an IV
infusion of 180mgm 2 IV infusion over 30min followed by
350mg IV infusion d,l-folinic acid or 175mg l-folinic acid over 2 h.
A 400mgm 2 IV bolus injection of 5-FU was then administered
over 5min followed by 2400mgm 2 5-flurouracil IV infusion
over 46 h. For the LV5FU2 regimen, irinotecan was omitted and
the 5-fluourouracil IV infusion dose was increased to
2800mgm 2. There were three different FOLFOXIRI regimens,
which were prescribed based on the patient’s age and WHO PS
status. The regimen for patients aged 70 years or less and with
PS¼ 0–1 contained 180mgm 2 irinotecan and 85mgm 2
oxaliplatin, 400mgm 2 5-fluorouracil bolus and 2400mgm 2
5-fluorouracil infusion. The individual components were reduced
to 80% of full dose for patientsX70 years or PS¼ 2 and to 60% for
patients X70 years and PS¼ 2. In arm D, cetuximab was
administered before chemotherapy as an IV dose of 500mgm 2,
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Figure 2. Diagram in patient information sheet 1 – given to patients to
explain the tests carried out on their tumour sample.
Table 1. Distribution of KRAS/BRAF and Topo-1 status
Topo-1 status
KRAS/BRAF status High (2–3) Low (0–1) No resulta Total
Either mutation 107 (78) 29 (23) 7 (4) 143 (105)
Both wild type/one wild type, other inconclusive 135 (109) 33 (23) 8 (5) 176 (137)
No resulta 2 (2) 0 (0) 11 (0) 13 (2)
Total 244 (189) 62 (46) 26 (9) 332 (244)
Abbreviation: Topo-1¼ topoisomerase 1.
a
No result due to either inconclusive result or missing or failed test.
Tests of association (for those with a test result only—bold entries in the table): Registered patients (n¼ 304): Pearson w2 on 1 d.f.¼ 0.13; P¼ 0.72. Randomised patients (n¼ 233): Pearson w2 on 1
d.f.¼ 1.03; P¼ 0.31. Numbers are: N registered (N randomised).
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whereas in arm E bevacizumab was administered first as a
5mg kg 1 IV infusion. All of the regimens are described in detail
in the FOCUS 3 protocol (Maughan and Meade, 2010).
If molecular results were not confirmed by 2 weeks, patients
could have one cycle of LV5FU2 before randomisation. Treatment
continued for at least 24 weeks or until disease progression on
treatment.
Patient symptoms were scored using National Cancer Institute
Common Toxicity Criteria for Adverse Events version 3.0. SAEs
and deaths, together with an assessment of causality, were
continuously reported; and were reassessed by an experienced
oncologist on behalf of the MRC.
CT scans were performed within 5 weeks before the start of
treatment and then 12 weekly on treatment and evaluated using
RECIST (v1.1) criteria. Responses were not confirmed by repeat
scans and external radiological review was not undertaken.
Statistical methods. Analyses were conducted according to a
predefined statistical analysis plan, which was approved by the
FOCUS3 TMG before database lock (first analysed in August 2011,
data updated for final analysis in May 2012).
For each of the co-primary process outcomes, an exact binomial
95% confidence interval was calculated around the result.
Exploratory analyses of the efficacy end points were planned in
relation to the four hypotheses stated above (Trial Design), which
in each case involved factorial analysis of two relevant molecular
subgroups, as illustrated in Figure 1. Time-to-event curves for
analysis of PFS were estimated using the Kaplan–Meier method.
All statistical analyses were carried out using Stata version 12
(StataCorp, College Station, TX, USA).
RESULTS
Patients. Between February 2010 and April 2011, 332 patients
from 24 centres in the UK were registered for the FOCUS3 trial.
Topo-1 status was determined in 306 patients (92%) and was
highly expressed (2–3) in 244 (73%). KRAS and BRAF status were
determined in 319 patients (96%), of whom 117 (37%) had a KRAS
mutation alone, 25 (8%) BRAF mutation alone, 1 (o1%) both
mutations, 169 (53%) were double wild type and 7 (2%) had a
BRAF mutation but inconclusive KRAS status. No association was
seen between topo-1 expression and KRAS/BRAF mutation status
(Table 1).
Of patients registered, 288 were eligible for randomisation, and
ultimately 244 (85%) were randomised. The reasons why patients
were not randomised are described in Figure 3 (Consort Diagram).
The main baseline characteristics and treatment allocation of all
randomised patients are shown in Table 2 (and in Supplementary
Tables 1 and 2) and Figure 3. The distribution of KRAS/BRAF and
Topo-1 status both at registration and randomisation is shown in
Table 1.
Primary process outcomes. The two co-primary process outcome
measures were not met. Of those patients randomised 180 (74%)
had their biomarker results within 10w.d. of registration (95%
CI¼ 68%, 79%). However, the results for 225 patients (92%) were
Registration (n =332)
Biomarker results
Randomised (n =244)
Patients registered and not randomised (n =88)
Low topo-1
both KRAS & BRAF
wildtype (n =33)
Not randomised
(n =10)
Not randomised
(n =6)
Not randomised
(n =27)
Not randomised
(n =28)
Not randomised
(n =3)
Not randomised
(n =3)
Not randomised
(n =0)
Not randomised
(n =11)
Randomised
(n =23)
Randomised
(n =23)
Randomised
(n =109)
Randomised
(n =78)
Randomised
(n =5)
Randomised
(n =4)
Randomised
(n =2)
A - Control arm
FOLFIRI (n =8)
B - LV5FU2
(n =8)
D - FOLFIRI +
cetuximab (n =7)
Regimen
Total
A - FOLFIRI 82
Patient change mind: 32•
•
•
•
•
•
•
•
•
Patient wanted specific regimen: 2
Results took too long: 1
Insufficient tumour material: 8
Found to be ineligible post registration: 21
Change in clinical circumstances: 13
Patient deceased: 8
Patient moved away: 1
Results inconclusive: 2
15
64
47
36
244
B - LV5FU2
C - FOLFOXIRI
D - FOLFIRI + cetuximab
E - FOLFIRI + bevacizumab
Number of patients
E - FOLFIRI +
bevacizumab
 (n =9)
D - FOLFIRI +
cetuximab (n =37)
E - FOLFIRI+
bevacizumab (n =25)
D - FOLFIRI+
cetuximab (n =3)
E - FOLFIRI+
bevacizumab (n =2)
B - LV5FU2
(n =7)
C - FOLFOXIRI
(n =37)
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(n =26)
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A - Control arm
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A - Control arm
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high topo-1 (n =2)
Inconclusive
results (n =11)
Figure 3. CONSORT diagram.
MRC FOCUS3 feasibility study BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.182 2181
available to investigators within 15w.d. of randomisation (95%
CI¼ 88%, 95%). The interval between registration and randomisa-
tion was less than or equal to 10w.d. in only 70 (29%) patients
(95% CI¼ 23%, 35%), which suggests delays due to clinical issues
(such as visit scheduling after results were available) had a greater
impact on timelines than delays in biomarker analysis
(Supplementary Table 3).
Reproducibility of biomarker results. 100% concordance was
achieved in the DNA mutation analysis results obtained between
the two reference laboratories. Initial crossing over of topo-1
samples between the laboratories produced consistent results,
although there were a higher proportion of ‘high’ expressing
tumours than was observed in FOCUS. The Cardiff centre was not
able to fully adopt the previously validated Leeds laboratory topo-1
protocol, and early in the trial it was realised that the protocols
adopted at the two centres were not giving uniformly consistent
results required for trial purposes. All subsequent sample testing
for KRAS, BRAF and topo-1 was therefore performed at Leeds.
Patient understanding. In all, 90–95% of participants self-
reported that they either fully or mostly understood all of the
aspects of the trial, see Figure 4. The areas that were least well
understood were the need to wait 2 weeks before start of treatment,
how treatment was allocated and what happens during treatment.
Qualitative research. In-depth, interviews with 14 randomised
patients were analysed using interpretative phenomenological
analysis and will be published in full elsewhere. The dominant
issue for the majority of participants was that they were discussing
the trial immediately following diagnosis of ACRC. This was a
greater concern than trial entry itself. Two of the fourteen
interviewees experienced delays with results from tumour testing,
Table 2. Baseline characteristics by treatment arm
Arm A
FOLFIRI
Arm B
LV5FU2
Arm C
FOLFOXIRI
Arm D
FOLFIRIþ cetux
Arm E
FOLFIRIþbev
Total
Treatment arm N % N % N % N % N % N %
Sex
Male 50 61 10 67 51 80 23 49 19 53 153 63
Female 32 39 5 33 13 20 24 51 17 47 91 37
Age at randomisation (years)
o45 7 9 0 0 5 8 3 6 3 8 18 7
45–54 13 16 1 7 15 23 5 11 6 17 40 16
55–64 35 43 4 27 29 45 19 40 11 31 98 40
65–74 20 24 7 47 13 20 16 34 10 28 66 27
75þ 7 9 3 20 2 3 4 9 6 17 22 9
WHO performance status
0¼Normal activity 43 52 8 53 35 55 23 49 12 33 121 50
1¼Restricted activity 34 41 7 47 25 39 22 47 20 56 108 44
2¼ Limited self-care 5 6 0 0 4 6 2 4 4 11 15 6
Prior radiotherapy
No 75 91 15 100 64 100 45 96 34 94 233 95
Yes 6 7 0 0 0 0 2 4 1 3 9 4
Missing 1 1 0 0 0 0 0 0 1 3 2 1
Adjuvant chemo
No 67 82 12 80 51 80 34 72 31 86 195 80
Yes, 1–6 months ago 2 2 0 0 1 2 2 4 1 3 6 2
Yes, 46 months ago 13 16 3 20 12 19 11 23 4 11 43 18
Total 82 100 15 100 64 100 47 100 36 100 244 100
Abbreviations: FOLFOXIRI¼ FOLFIRI and oxaliplatin; WHO¼World Health Organization.
0
Q1 Q2
I understood fully I didn't fully understand
I didn't understand at all
No response given
I understood mostly
I'm not sure I understood
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Figure 4. Patient understanding of the consent process. Q1:
Understanding of PIS2. Q2: Understanding why tumour was tested. Q3:
Understanding of different treatments. Q4: Understanding of why you
had to wait 2 weeks. Q5: Understanding of how treatment was
allocated. Q6: Understanding of what happens during treatment. Q7:
Understanding of request to give blood, complete questionnaire, take
part in an interview.
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causing significant distress. The majority of patients expressed no
concern with tumour testing times but highlighted distress caused
by prior delays during diagnosis and treatment.
Relationships with family were key to ongoing practical and
emotional support and particularly relevant to the decision to enrol
on the trial and the processing of information. The multiple roles
of the CRN emerged in relation to recruitment and the ongoing
care of participants in the trial. Reasons for enrolling in FOCUS3
related to altruism, perception of the trial as offering personalised
treatment and better care, finding a cure for cancer and being the
only option available.
Treatment and follow-up. Of the 244 randomised patients, 4 did
not commence treatment—2 from arm A and 2 from arm E. Of the
remaining 240, two patients (0.8%) received a single initial cycle of
LV5FU2 alone before commencing their allocated regimens. Full-
dose FOLFOXIRI was initiated in the 86% of patients with high
topo-1 who wereo70 and PFS 0–1; the remainder commenced at
lower doses as per protocol. The median number of cycles of
treatment delivered was 12 (IQR¼ 7–13).
Efficacy outcomes. Efficacy outcomes were assessed in May 2012
when the median duration of follow-up was 15.2 months
(IQR¼ 12.6–18.8 months).
In patients with low topo-1 (B vs A, n¼ 30), 12-week RR was
60% with LV5FU2 alone and 47% with FOLFIRI, supporting the
original hypothesis that irinotecan does not add benefit in this
group. There was no evidence of a difference in PFS.
There was no improvement in RR (40% vs 45%) or in PFS
(HR¼ 1.08 (0.67–1.76)) with the addition of oxaliplatin (n¼ 127)
to FOLFIRI (C vs A). The complex randomisation algorithm
resulted in a gender imbalance with more males in this group,
which has uncertain relevance.
In patients with KRAS and BRAF wild type (D vs A, n¼ 92), the
addition of cetuximab to FOLFIRI was associated with an increased
RR (44% vs 66%) and PFS (HR¼ 0.44 (0.23–0.82)), consistent with
the results of the phase III Crystal trial (Van Cutsem et al, 2009,
2011).
For the addition of bevacizumab to FOLFIRI in patients with
KRAS or BRAF mutations (E vs A, n¼ 72), there was an observed
increased RR (47% vs 33%). No PFS benefits were observed.
Kaplan–Meier survival curves are presented in Figure 5 and 12-
week RR data are summarised in Table 3.
Toxicity. Toxicity observed was as expected for the LV5FU2,
FOLFIRI, FOLFIRIþ cetuximab and FOLFIRIþ bevacizumab
regimens. The anticipated increased toxicity of the FOLFOXIRI
regimen was minimal, with only 27% grade 3þ neutropenia.
This may be due to the reduced dosing schedule in the elderly/less
fit patients (n¼ 9 of 127) previously described (Supplementary
Table 4).
DISCUSSION
The primary objective of FOCUS3 was to assess the feasibility of
undertaking a complex biomarker-driven trial in a national
multicentre setting. Although the study did not meet either of its
ambitious pre-specified co-primary process outcome measures, the
trial has shown that complex prospective biomarker-driven RCTs
are possible on a substantial scale across the United Kingdom.
Extra resources are required in the reference pathology laboratories
to undertake the biomarker analyses, but within investigator sites
and the trials office there is no requirement for special dedicated
staff.
Potentially eligible patients were necessarily approached for
consent at precisely the time when they had recently learned of the
life-threatening status of their disease; our qualitative research
showed this was the dominating concern in their minds. That we
achieved our target patient number from 24 centres in 1 year
demonstrated that the strategy for explaining the trial was
successful and that, even under difficult circumstances, complex
trials can be attractive to patients. Our four-step consent procedure
was developed in consultation with patients and carers and was
praised by the research ethics committee. The responses to the
questionnaire administered after patients had read their stage 2 PIS
showed high levels of understanding of the trial. The subsequent
steps in the consent process, with specific patient consent forms for
each molecular cohort and for each treatment, avoided information
overload and provided only that information that was specifically
relevant to the particular patient.
The logistics of retrieval of the FFPE blocks from the diagnostic
hospitals was a major concern. Prior written agreement, a modest
(d15) fee for retrieval and detailed sample tracking by CTU
personnel minimised delay. The critical lessons were the need for
excellent communication between all parties in the chain: from
CRN to pathologist to the central laboratories to the coordinating
trials unit.
A delay in reporting analysis results back to the MRC CTU was
observed in 22 cases and was distressing to some patients. The
delays were due to insufficient tumour in the block (n¼ 4),
unexpected technical difficulties (n¼ 6), initial testing inconclusive
or failed (n¼ 12). This was mitigated by allowing patients (n¼ 2)
to start cycle one of chemotherapy using the infusional 5-FU and
folinic acid backbone, which was common to all treatment
protocols and then adding in the relevant additional agents for
cycle 2 once the biomarker results were available.
Overall, the most important laboratory issue was reproducibility
of IHC results. Although 100% concordance was achieved in the
calling of KRAS and BRAF mutations between the two laboratories,
it proved very difficult to perform and report the topo-1 IHC
staining intensity in a sufficiently comparable way. Owing to
technical- and manpower-based organisational limitations, it was
not possible to completely replicate the manual staining metho-
dology adopted initially by the Leeds laboratory in the Cardiff
laboratory where an automated staining platform was used. Even
what were deemed inconsequential differences between staining
protocols contributed to this lack of consistency. For future studies,
contributing diagnostic centres will use the same antibodies,
protocol and automated staining platform. Detailed guidance on
scoring, blinded replication in contributing centres with face to
face comparison of discrepantly scored sections have been
implemented for IHC tests in FOCUS4. On trial quality assurance
by double reading of slides will ensure comparability of evaluation.
This trial was structured so that we could address four distinct
hypotheses, any or all of which might be the subject of a
subsequent phase III trial. Our first hypothesis, arising from the
observation in the earlier FOCUS trial that patients with low
topo-1 expression appear to gain no benefit from the addition of
irinotecan to LV5FU2 (Seymour et al, 2007; Braun et al, 2008), was
supported and remains an intriguing one. Only 30 patients were
randomised to this comparison because of the lower than expected
rate of low topo-1 expression, but the high RR (60%) in the
LV5FU2 only treated patients suggests further work in this area
might be rewarding.
The second hypothesis proposed that patients with high topo-1
expression, who alone in FOCUS gained benefit from either
irinotecan or oxaliplatin in comparison to 5-FU (Braun et al,
2008), may derive additional benefit from the triple chemotherapy
regimen. With the protocol-specified dose reductions, the regimen
was well tolerated. However, in contrast to the international
literature (Falcone et al, 2007, 2013), although patients had a
minimally higher RR, there was no hint of a PFS benefit.
The third hypothesis, tested in 92 patients with KRAS and
BRAF wild-type tumours, was that the addition of cetuximab
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would increase efficacy. This recapitulated the Crystal study
(Van Cutsem et al, 2009, 2011) and benefits in PFS and RR were observed.
Finally, our fourth hypothesis for patients with KRAS or BRAF
mutations (72 patients) was based on the limited data that
bevacizumab retains efficacy in these patients (Ince et al, 2005). No
benefits on either RR or PFS were observed.
The FOCUS4 trial programme (Kaplan et al, 2013) has recently
opened to recruitment building on many of the lessons learned in
FOCUS3. Patient and clinician enthusiasm for biomarker-stratified
trials and the rapid accrual observed in FOCUS3 have encouraged
us to be optimistic in our predicted recruitment targets: 2400
registered patients with over 1500 randomised into multiple
biomarker-directed comparisons in 4 years for FOCUS4. Staged
PISs have been designed with information given at the time of
registration limited to that which is necessary for consent for
release of tumour blocks, plus a minimal outline of the protocol so
as to avoid information overload. Detailed quality assurance work
has been undertaken between the two biomarker reference
laboratories, especially for the IHC tests (PTEN and mismatch
repair proteins). In FOCUS4, the allocation by biomarker to
specific comparisons occurs for patients with stable or responding
disease after 4 months of first-line chemotherapy. Knowing that in
FOCUS3 we completed biomarker analysis in 99% of patients
within 20w.d. of consent, the FOCUS4 logistics (registration of
patients up to 12 weeks into their first-line chemotherapy) should
facilitate accrual. Detailed engagement with pathologists in
referring hospitals and a relatively small (d15) payment per case
enabled rapid release of blocks for central analysis in FOCUS3 and
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D vs A; KRAS/BRAF-wt Unstratified 0.77 (0.49, 1.21)
(n = 92) Stratified 0.44 (0.23, 0.82)
E vs A; KRAS/BRAF-mut Unstratified 0.97 (0.58, 1.61)
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Figure 5. Treatment comparisons – progression-free survival.
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the same pattern has been used in FOCUS4. Perhaps most
important is the strength of the team working established through
FOCUS3, including patient representatives, clinicians, biomarker
experts (including histopathologists, immunohistochemists, geneti-
cists and technicians), statisticians, research nurses, pharmacists,
trial managers and data managers. To this, we have added research
network managers to ensure improved patient transfers between
district general hospitals and experimental cancer medicine
centres, who are required in FOCUS4 for some patients
randomised to the novel agent combinations being studied.
CONCLUSION
The FOCUS3 trial was a feasibility study designed to address the
challenges of patient acceptability, technical logistics, and to test a
novel design for examining the predictive role of biomarkers for
first-line therapy of ACRC. We have shown that such studies are
feasible and very well received by participants. The central trial
design concepts have been taken forward into a major UK trial
programme FOCUS4-molecular selection of therapy in CRC: a
molecularly stratified RCT programme, which opened to accrual in
January 2014 (Kaplan et al, 2013).
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